MSH|^~\&|LAB|CONRAD|OPMED|12388|20110516171816||ORU^R01|20110523114411037|P|2.3|||||||PID|1|3333|005483612^^^GLIMS||Test^Patient||20080920|F|||Spezialort^^Luzern^6003^CH|||||ORC|RE||10-00000128S^10||A||^^^20110513180408|||CONRAD||TESTA|||20110516000000|||||OBR|1||10-00000128S^10|||20110513180400|20110513180400|||||||20110513180408||TESTA^Test Arzt^^^^^^GLIMS||||||20110516000000|||P||OBX|1|SN|prot^Eiweiss^GLIMS||75.0|g/l|60.0-80.0|N|||F||||||OBX|2|SN|albu^Albumin^GLIMS||39.5|g/l|38.0-54.0|N|||F||||||OBX|3|SN|KAPF^Freie Kappa-Leichtketten^GLIMS||5.35|mg/l|3.30-19.40|N|||F||||||OBX|4|SN|LAMF^Freie Lambda-Leichtketten^GLIMS||10.00|mg/l|5.70-26.30|N|||F||||||OBX|5|SN|KALAFQ^Quotient Kappa/Lambda^GLIMS||0.53|Ratio|0.26-1.65|N|||F||||||OBX|6|SN|ALBPR^Albumin^GLIMS||66.0|%|55.8-66.1|N|||F||||||OBX|7|SN|A1G^Alpha-1-Globuline^GLIMS||3.0|%|2.9-4.9|N|||F||||||OBX|8|SN|A2G^Alpha-2-Globuline^GLIMS||10.0|%|7.1-11.8|N|||F||||||OBX|9|SN|B1G^Beta-1-Globuline^GLIMS||6.0|%|4.7-7.2|N|||F||||||OBX|10|SN|B2G^Beta-2-Globuline^GLIMS||5.0|%|3.2-6.5|N|||F||||||OBX|11|SN|GG^Gamma-Globuline^GLIMS||10.0|%|11.1-18.8|L|||F||||||OBX|12|SN|A1GA^Alpha-1-Globuline^GLIMS||2.2|g/l|2.1-3.5|N|||F||||||OBX|13|SN|A2GA^Alpha-2-Globuline^GLIMS||7.5|g/l|5.1-8.5|N|||F||||||OBX|14|SN|B1GA^Beta-1-Globuline^GLIMS||4.5|g/l|3.4-5.2|N|||F||||||OBX|15|SN|B2GA^Beta-2-Globuline^GLIMS||3.8|g/l|2.3-4.7|N|||F||||||OBX|16|SN|GGA^Gamma-Globuline^GLIMS||7.5|g/l|8.0-13.5|L|||F||||||